Spyre Therapeutics, Inc. (SYRE) is listed on NASDAQ in Pharmaceutical Stocks. It is $90.36, -3.48%, with a $8.0B market cap. RSI is 35.0, near oversold. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 35.0 Near Oversold
Market Cap $8.0B
Volume 1.1M
Fundamentals — 10-Q Q2 2026
Revenue --
Net Income $-105.2M
EPS $-1.09
P/E Ratio -82.9x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director | Sell | 23,000 | $104.53 | $2.4M | 2026 Aug 7 |
| Burrows Scott L | Chief Financial Officer | Sell | 7,500 | $95.57 | $716,771 | 2026 Aug 3 |
| Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $95.51 | $1.4M | 2026 Aug 3 |
| Burrows Scott L | Chief Financial Officer | Sell | 7,500 | $87.74 | $658,040 | 2026 Jul 1 |
| Sloan Sheldon | Chief Medical Officer | Sell | 8,334 | $87.70 | $730,896 | 2026 Jul 1 |
| Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $87.69 | $1.3M | 2026 Jul 1 |
| Burrows Scott L | Chief Financial Officer | Sell | 15,000 | $87.13 | $1.3M | 2026 Jun 25 |
| Fairmount Funds Management LLC | Director | Sell | 4,684,781 | $85.31 | $399.7M | 2026 Jun 23 |
| Henderson Michael Thomas | Director | Sell | 20,000 | $100.00 | $2.0M | 2026 Jun 22 |
| Sloan Sheldon | Chief Medical Officer | Sell | 8,333 | $75.00 | $624,975 | 2026 Jun 3 |
| Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $70.43 | $1.1M | 2026 Jun 1 |
| Burrows Scott L | Chief Financial Officer | Sell | 7,500 | $71.06 | $532,937 | 2026 Jun 1 |
| Henderson Michael Thomas | Director | Sell | 80,000 | $74.40 | $6.0M | 2026 May 8 |
| Burrows Scott L | Chief Financial Officer | Sell | 12,500 | $71.37 | $892,125 | 2026 May 1 |
| Sloan Sheldon | Chief Medical Officer | Sell | 78,333 | $71.50 | $5.6M | 2026 May 1 |
| Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $71.37 | $1.1M | 2026 May 1 |
| Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $49.33 | $739,912 | 2026 Apr 1 |
| Sloan Sheldon | Chief Medical Officer | Sell | 7,958 | $50.00 | $397,900 | 2026 Apr 1 |
| Burrows Scott L | Chief Financial Officer | Sell | 7,500 | $49.34 | $370,076 | 2026 Apr 1 |
| Burrows Scott L | Chief Financial Officer | Sell | 2,500 | $40.65 | $101,620 | 2026 Mar 3 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $44.82 | 51.9 | -- |
| | $16.34 | 45.3 | $18.8B |
| | $47.41 | 37.2 | $8.0B |
| | $61.02 | 60.3 | $10.1B |
Take SYRE further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put SYRE in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Spyre Therapeutics, Inc. next reports.
Set alerts on SYRE
Get notified when Spyre Therapeutics, Inc. hits your price targets or technical conditions are met.
Get Started Free